Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
Nicole K Kiss, Linda Denehy, Lara Edbrooke, Carla M Prado, David Ball, Shankar Siva, Gavin Abbott, Anna Ugalde, Steve F Fraser, Sarah Everitt, Nicholas Hardcastle, Andrew Wirth, Robin M Daly
BMJ OPEN | BMJ PUBLISHING GROUP | Published : 2021
INTRODUCTION: Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding of the magnitude, determinants and clinical significance of these muscle abnormalities in the lung cancer CRT/RT population. The primary objective of this study is to identify the predictors of muscle abnormalities (low muscle mass and muscle attenuation) and their depletion over time in people with lung cancer receiving CRT/RT. Secondary objectives are to assess the magnitude of change in these p..View full abstract
Awarded by Victorian Cancer Agency Nursing and Allied Health Clinical Research Fellowship
NKK and this study are supported by a Victorian Cancer Agency Nursing and Allied Health Clinical Research Fellowship (grant no: CRFNAH18001).